Adding Vitamin E-TPGS to the Formulation of Genexol-PM: Specially Mixed Micelles Improve Drug-Loading Ability and Cytotoxicity against Multidrug-Resistant Tumors Significantly
Authors:
Open Access
- 1 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (4) , e0120129
Abstract
Genexol-PM, produced by Samyang Company (Korea) is an excellent preparation of paclitaxel (PTX) for clinical cancer treatment. However, it cannot resolve the issue of multidrug resistance (MDR)—a significant problem in the administration of PTX to cancer patients. To increase the efficacy of Genexol-PM against MDR tumors, a mixed micelle capable of serving as a vehicle for PTX was developed, and two substances were chosen as carrier materials: 1) Polyethylene glycol–polylactic acid (PEG-PLA), the original vehicle of Genexol-PM. 2) Vitamin E-TPGS, an inhibitor of P-glycoprotein (P-gp). P-gp has been proven to be the main cause of MDR. In vitro evaluation indicated that the mixed micelle was an ideal PTX delivery system for the treatment of MDR tumors; the mixed micelle also showed a significantly better drug-loading coefficient than Genexol-PM.Keywords
This publication has 38 references indexed in Scilit:
- Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluationInternational Journal of Nanomedicine, 2013
- Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancerInternational Journal of Nanomedicine, 2012
- Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinumInvestigational New Drugs, 2011
- Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered ReleasePharmaceutical Research, 2010
- Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P1231Acta Pharmacologica Sinica, 2006
- Cyclooxygenase-independent down-regulation of multidrug resistance–associated protein-1 expression by celecoxib in human lung cancer cellsMolecular Cancer Therapeutics, 2005
- Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implicationsJournal of Cancer Research and Clinical Oncology, 2005
- Diode-array UV spectrometric evidence for a concentration dependent phase transition in dilute aqueous solutions of pluronic F87 (poloxamer 237)Journal of the Chemical Society, Chemical Communications, 1995
- Optimized synthesis of polyglutaraldehyde nanoparticles using central composite designJournal of Pharmaceutical Sciences, 1988
- Growth Characteristics of Human Melanoma Multicellular Spheroids In Liquid‐Overlay Culture: Comparisons With the Parent Tumour XenograftsCell Proliferation, 1986